FDA Approved: KEPPRA XR — Supplemental Application (UCB, Inc.)

View source ↗

Summary

FDA approved a supplemental application for KEPPRA XR (levetiracetam), authorizing the extended-release formulation from UCB, for use in epilepsy as adjunctive …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy
• Partial-onset Seizures

Drugs mentioned

• KEPPRA XR (levetiracetam)

Snippet

SUPPL AP for KEPPRA XR (LEVETIRACETAM)